Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.41
ALXN's Cash to Debt is ranked lower than
87% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. ALXN: 0.41 )
Ranked among companies with meaningful Cash to Debt only.
ALXN' s 10-Year Cash to Debt Range
Min: 0.41  Med: 2.98 Max: No Debt
Current: 0.41
Equity to Asset 0.65
ALXN's Equity to Asset is ranked lower than
54% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALXN: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
ALXN' s 10-Year Equity to Asset Range
Min: 0.04  Med: 0.68 Max: 0.95
Current: 0.65
0.04
0.95
Interest Coverage 291.32
ALXN's Interest Coverage is ranked lower than
82% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 291.32 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s 10-Year Interest Coverage Range
Min: 14.38  Med: 178.82 Max: 9999.99
Current: 291.32
14.38
9999.99
F-Score: 4
Z-Score: 5.77
M-Score: -1.99
WACC vs ROIC
11.13%
17.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 30.33
ALXN's Operating margin (%) is ranked higher than
92% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. ALXN: 30.33 )
Ranked among companies with meaningful Operating margin (%) only.
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21  Med: -138.47 Max: 38.89
Current: 30.33
-10370.21
38.89
Net-margin (%) 24.78
ALXN's Net-margin (%) is ranked higher than
89% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. ALXN: 24.78 )
Ranked among companies with meaningful Net-margin (%) only.
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86  Med: -128.11 Max: 76.31
Current: 24.78
-10220.86
76.31
ROE (%) 13.86
ALXN's ROE (%) is ranked higher than
86% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ALXN: 13.86 )
Ranked among companies with meaningful ROE (%) only.
ALXN' s 10-Year ROE (%) Range
Min: -136.75  Med: -26.56 Max: 63.11
Current: 13.86
-136.75
63.11
ROA (%) 10.14
ALXN's ROA (%) is ranked higher than
89% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. ALXN: 10.14 )
Ranked among companies with meaningful ROA (%) only.
ALXN' s 10-Year ROA (%) Range
Min: -45.22  Med: -16.03 Max: 46.71
Current: 10.14
-45.22
46.71
ROC (Joel Greenblatt) (%) 97.28
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. ALXN: 97.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -902.5  Med: -209.62 Max: 173.86
Current: 97.28
-902.5
173.86
Revenue Growth (3Y)(%) 39.50
ALXN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ALXN: 39.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALXN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5  Med: 39.10 Max: 498.1
Current: 39.5
-70.5
498.1
EBITDA Growth (3Y)(%) 52.40
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ALXN: 52.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALXN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.1  Med: 29.50 Max: 72.8
Current: 52.4
-10.1
72.8
EPS Growth (3Y)(%) 53.00
ALXN's EPS Growth (3Y)(%) is ranked higher than
93% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ALXN: 53.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALXN' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.3  Med: 14.50 Max: 77.3
Current: 53
-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ALXN Guru Trades in Q3 2014

Paul Tudor Jones 3,120 sh (+135.29%)
Ron Baron 12,941 sh (+27.56%)
Andreas Halvorsen 2,198,451 sh (+9.59%)
Frank Sands 5,311,488 sh (+0.60%)
Pioneer Investments 30,500 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Jim Simons 206,152 sh (-16.05%)
Joel Greenblatt 1,804 sh (-89.45%)
» More
Q4 2014

ALXN Guru Trades in Q4 2014

Ray Dalio 18,513 sh (New)
Joel Greenblatt 85,974 sh (+4665.74%)
Ron Baron 18,366 sh (+41.92%)
Pioneer Investments 30,795 sh (+0.97%)
Frank Sands 5,267,903 sh (-0.82%)
Frank Sands 5,267,903 sh (-0.82%)
Jim Simons 152,552 sh (-26.00%)
Paul Tudor Jones 1,487 sh (-52.34%)
Andreas Halvorsen 390,271 sh (-82.25%)
» More
Q1 2015

ALXN Guru Trades in Q1 2015

Lee Ainslie 1,350 sh (New)
Ron Baron 41,163 sh (+124.13%)
Paul Tudor Jones 3,231 sh (+117.28%)
Jim Simons 313,952 sh (+105.80%)
Ray Dalio 29,099 sh (+57.18%)
Pioneer Investments 31,941 sh (+3.72%)
Andreas Halvorsen Sold Out
Frank Sands 5,204,296 sh (-1.21%)
Joel Greenblatt 23,261 sh (-72.94%)
» More
Q2 2015

ALXN Guru Trades in Q2 2015

Andreas Halvorsen 201,756 sh (New)
David Swensen 319,273 sh (New)
Mario Gabelli 1,415 sh (New)
Ron Baron 69,764 sh (+69.48%)
Frank Sands 6,519,546 sh (+25.27%)
Lee Ainslie 1,600 sh (+18.52%)
Pioneer Investments 32,062 sh (+0.38%)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Paul Tudor Jones 1,501 sh (-53.54%)
Jim Simons 13,442 sh (-95.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Alexion Pharmaceuticals Inc

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Aug 19, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry.





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF
In 30 years as chief investment officer at Yale University, David Swensen (Trades, Portfolio) has been quite successful. In the last decade, he has enjoyed an annual return of more than 17.2% on his investments. In his personal investments, Swensen applies knowledge he has gained in that role as well as in his six years on Wall Street prior to taking the job at Yale Read more...
Baron Funds Comments on Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry. Read more...
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Alexion Pharmaceuticals Inc, Equity Residential, and Tableau Software Inc. Read more...
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY
According to GuruFocus Insider Data, the largest insider sells during the past week were: Oracle Corporation (NYSE:ORCL), Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Waters Corp (NYSE:WAT) and DENTSPLY International Inc (NASDAQ:XRAY). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 60.97
ALXN's P/E(ttm) is ranked lower than
69% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. ALXN: 60.97 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92  Med: 72.57 Max: 1113.68
Current: 60.97
13.92
1113.68
Forward P/E 32.57
ALXN's Forward P/E is ranked lower than
66% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. ALXN: 32.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 59.50
ALXN's PE(NRI) is ranked lower than
70% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. ALXN: 59.50 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s 10-Year PE(NRI) Range
Min: 13.96  Med: 72.83 Max: 1058
Current: 59.5
13.96
1058
P/B 4.74
ALXN's P/B is ranked lower than
54% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ALXN: 4.74 )
Ranked among companies with meaningful P/B only.
ALXN' s 10-Year P/B Range
Min: 3.05  Med: 10.65 Max: 162.14
Current: 4.74
3.05
162.14
P/S 15.10
ALXN's P/S is ranked lower than
58% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. ALXN: 15.10 )
Ranked among companies with meaningful P/S only.
ALXN' s 10-Year P/S Range
Min: 9.66  Med: 17.31 Max: 1115.3
Current: 15.1
9.66
1115.3
PFCF 58.02
ALXN's PFCF is ranked lower than
61% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 39.55 vs. ALXN: 58.02 )
Ranked among companies with meaningful PFCF only.
ALXN' s 10-Year PFCF Range
Min: 40  Med: 62.54 Max: 99999999.99
Current: 58.02
40
99999999.99
POCF 43.81
ALXN's POCF is ranked lower than
59% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. ALXN: 43.81 )
Ranked among companies with meaningful POCF only.
ALXN' s 10-Year POCF Range
Min: 33.16  Med: 51.42 Max: 83.87
Current: 43.81
33.16
83.87
EV-to-EBIT 58.01
ALXN's EV-to-EBIT is ranked lower than
73% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. ALXN: 58.01 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s 10-Year EV-to-EBIT Range
Min: -98.6  Med: 43.80 Max: 893.9
Current: 58.01
-98.6
893.9
PEG 1.14
ALXN's PEG is ranked higher than
79% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.26 vs. ALXN: 1.14 )
Ranked among companies with meaningful PEG only.
ALXN' s 10-Year PEG Range
Min: 0.68  Med: 1.31 Max: 2.63
Current: 1.14
0.68
2.63
Shiller P/E 103.59
ALXN's Shiller P/E is ranked lower than
74% of the 113 Companies
in the Global Biotechnology industry.

( Industry Median: 44.53 vs. ALXN: 103.59 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s 10-Year Shiller P/E Range
Min: 93.17  Med: 133.51 Max: 655.33
Current: 103.59
93.17
655.33
Current Ratio 3.29
ALXN's Current Ratio is ranked lower than
58% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ALXN: 3.29 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s 10-Year Current Ratio Range
Min: 1.38  Med: 7.81 Max: 52.92
Current: 3.29
1.38
52.92
Quick Ratio 2.99
ALXN's Quick Ratio is ranked lower than
58% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. ALXN: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s 10-Year Quick Ratio Range
Min: 1.38  Med: 7.18 Max: 52.92
Current: 2.99
1.38
52.92
Days Inventory 285.24
ALXN's Days Inventory is ranked lower than
85% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. ALXN: 285.24 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s 10-Year Days Inventory Range
Min: 202.61  Med: 330.15 Max: 959.95
Current: 285.24
202.61
959.95
Days Sales Outstanding 81.79
ALXN's Days Sales Outstanding is ranked lower than
63% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ALXN: 81.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s 10-Year Days Sales Outstanding Range
Min: 70.74  Med: 113.85 Max: 451.45
Current: 81.79
70.74
451.45

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.16
ALXN's Price/Projected FCF is ranked higher than
63% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ALXN: 3.16 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s 10-Year Price/Projected FCF Range
Min: 3.17  Med: 6.00 Max: 142.19
Current: 3.16
3.17
142.19
Price/Median PS Value 0.88
ALXN's Price/Median PS Value is ranked higher than
65% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. ALXN: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.17 Max: 59.4
Current: 0.88
0.36
59.4
Price/Peter Lynch Fair Value 2.46
ALXN's Price/Peter Lynch Fair Value is ranked lower than
58% of the 52 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. ALXN: 2.46 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56  Med: 2.80 Max: 4.22
Current: 2.46
0.56
4.22
Earnings Yield (Greenblatt) (%) 1.74
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ALXN: 1.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 2.10 Max: 3
Current: 1.74
0.1
3
Forward Rate of Return (Yacktman) (%) 47.50
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
93% of the 100 Companies
in the Global Biotechnology industry.

( Industry Median: 13.39 vs. ALXN: 47.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -18.5  Med: 0.30 Max: 75.6
Current: 47.5
-18.5
75.6

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 2,644 3,460 4,109
EPS($) 3.91 5.52 6.75
EPS without NRI($) 3.91 5.52 6.75

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ALXN.Switzerland, AXP.Germany, 0QZM.UK,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF Aug 19 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Aug 19 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 

More From Other Websites
UBS Picks 22 Stocks for Their 'Cash Cushions' for Times of Market Volatility Aug 28 2015
How Big Biotech Spends Its Money Aug 21 2015
Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN) Aug 21 2015
Celgene May be The Single Best Biotech in the World Aug 19 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Aug 17 2015
Don’t Miss White-Hot Baker Bros.’ New Healthcare Picks Aug 17 2015
Biotech, Semiconductor ETFs Enter Dangerous Ground Aug 14 2015
Short Sellers Wary Of Biotech Stocks Aug 14 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K/A, Financial Statements and Exhibits Aug 13 2015
JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015 Aug 13 2015
3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming Aug 10 2015
What’s Shire’s plan for Baxalta? Inside CEO Flemming Ornskov’s head Aug 07 2015
Will Gilead Make 'Transformative Transaction'? Aug 07 2015
Corruption Currents: Hacking Computers to Send Data Via Sound Waves Aug 06 2015
ALEXION PHARMACEUTICALS INC Financials Aug 06 2015
Amgen, Inc. Earnings Analysis: By the Numbers Q2*, 2015 Aug 06 2015
3 Potential Huge Takeover Targets in Biotech Aug 04 2015
10-Q for Alexion Pharmaceuticals, Inc. Aug 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK